JP2023533679A5 - - Google Patents

Info

Publication number
JP2023533679A5
JP2023533679A5 JP2022579760A JP2022579760A JP2023533679A5 JP 2023533679 A5 JP2023533679 A5 JP 2023533679A5 JP 2022579760 A JP2022579760 A JP 2022579760A JP 2022579760 A JP2022579760 A JP 2022579760A JP 2023533679 A5 JP2023533679 A5 JP 2023533679A5
Authority
JP
Japan
Prior art keywords
group
delivery system
drug delivery
linkage
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022579760A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533679A (ja
JP7870259B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/105899 external-priority patent/WO2022012492A1/en
Publication of JP2023533679A publication Critical patent/JP2023533679A/ja
Publication of JP2023533679A5 publication Critical patent/JP2023533679A5/ja
Application granted granted Critical
Publication of JP7870259B2 publication Critical patent/JP7870259B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022579760A 2020-07-15 2021-07-13 治療剤を局所的に送達するための薬物送達システムおよびその使用 Active JP7870259B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/102115 2020-07-15
CN2020102115 2020-07-15
PCT/CN2021/105899 WO2022012492A1 (en) 2020-07-15 2021-07-13 Drug delivery system for locally delivering therapeutic agents and uses thereof

Publications (3)

Publication Number Publication Date
JP2023533679A JP2023533679A (ja) 2023-08-04
JP2023533679A5 true JP2023533679A5 (cg-RX-API-DMAC7.html) 2024-07-12
JP7870259B2 JP7870259B2 (ja) 2026-06-04

Family

ID=79555042

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022579760A Active JP7870259B2 (ja) 2020-07-15 2021-07-13 治療剤を局所的に送達するための薬物送達システムおよびその使用

Country Status (10)

Country Link
US (1) US20230256106A1 (cg-RX-API-DMAC7.html)
EP (1) EP4181963A4 (cg-RX-API-DMAC7.html)
JP (1) JP7870259B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230040957A (cg-RX-API-DMAC7.html)
CN (2) CN117838875B (cg-RX-API-DMAC7.html)
AU (1) AU2021310171A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022021179A2 (cg-RX-API-DMAC7.html)
CA (1) CA3179897A1 (cg-RX-API-DMAC7.html)
IL (1) IL297377A (cg-RX-API-DMAC7.html)
WO (1) WO2022012492A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114907353A (zh) * 2021-02-09 2022-08-16 明慧医药(杭州)有限公司 一种前药化合物及其制备方法和用途
KR20240027732A (ko) * 2021-07-20 2024-03-04 코발 바이오파마 (상하이) 컴퍼니 리미티드 외용 항염증 결합 화합물 약물 및 그 제조 방법과 응용
AU2022348759A1 (en) * 2021-09-16 2024-01-25 Coval Biopharma (Shanghai) Co., Ltd. Drug delivery system for locally delivering therapeutic agents and uses thereof
WO2023155905A1 (zh) * 2022-02-21 2023-08-24 上海岸阔医药科技有限公司 化合物及其用途
KR20250012423A (ko) * 2023-07-17 2025-01-24 차의과학대학교 산학협력단 금 나노입자 및 상환변환 나노입자로부터 형성된 일시적 광천공을 위한 나노복합체
WO2026002095A1 (en) * 2024-06-26 2026-01-02 Coval Biopharma (Shanghai) Co., Ltd. Drug delivery system for locally controlled release of therapeutic agents and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITPD20020271A1 (it) * 2002-10-18 2004-04-19 Fidia Farmaceutici Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.
CN101921347B (zh) 2004-01-07 2014-07-30 生化学工业株式会社 透明质酸衍生物及含有其的药剂
WO2006122954A2 (en) * 2005-05-18 2006-11-23 Eurand Pharmaceuticals Limited Antiproliferative conjugates comprising hyaluronic acid and n-derivatives of glutamic acid
IE20060049A1 (en) * 2006-01-25 2007-08-08 Eurand Pharmaceuticals Ltd A novel drug delivery system: use of hyaluronic acid as a carrier moleclue for different classes of therapeutic active agents
IE20060565A1 (en) * 2006-07-28 2008-02-06 Eurand Pharmaceuticals Ltd Drug delivery system based on regioselectively amidated hyaluronic acid
IE20070900A1 (en) * 2007-12-12 2009-06-24 Eurand Pharmaceuticals Ltd New anticancer conjugates
US9789200B2 (en) * 2008-04-22 2017-10-17 Fidia Farmaceutici S.P.A. Therapeutic use of new pharmaceutical preparations containing antitumoral drugs bound to hyaluronic acid in the treatment of neoplasias
CN101745119B (zh) * 2010-01-25 2012-07-25 中国药科大学 羧酸类药物-多糖偶联物及其制备方法与应用
BR112014032916A2 (pt) * 2012-06-28 2017-08-01 Pfizer anticorpos anti-fármacos e usos destes para o monitoramento de fármaco
CN104603156B (zh) * 2012-09-05 2016-10-26 中外制药株式会社 引入有氨基酸和甾基的透明质酸衍生物
KR101467076B1 (ko) * 2013-02-20 2014-12-02 성균관대학교산학협력단 히알루론산-메토트렉세이트 접합체를 포함하는 관절염 예방 또는 치료용 약학적 조성물 및 이의 제조방법
CN103751795B (zh) * 2013-05-20 2017-02-08 中国药科大学 透明质酸‑抗肿瘤药偶联物及复合纳米粒组合物的制备和应用
US10098962B2 (en) * 2013-07-10 2018-10-16 Seikagaku Corporation Glycosaminoglycan derivative and method for producing same
US9572832B2 (en) * 2013-08-29 2017-02-21 Holy Stone Healthcare Co., Ltd. Compound of glycosaminoglycan and its fabrication method as well as application
CN104491875A (zh) * 2014-12-22 2015-04-08 中国药科大学 一种基于透明质酸-难溶性药物前药的自聚纳米系统的制备方法
CN107096036B (zh) * 2017-04-12 2020-01-14 武汉理工大学 一种pH敏感型透明质酸-多柔比星纳米前药的制备方法及其应用
JOP20190245A1 (ar) * 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
CN108467439A (zh) * 2018-03-22 2018-08-31 盐城师范学院 一种水溶性紫杉醇抗癌药物的制备方法
JP2022510986A (ja) * 2018-12-12 2022-01-28 エージェンシー フォー サイエンス,テクノロジー アンド リサーチ ヒアルロン酸およびエピガロカテキン-3-o-没食子酸のコンジュゲートおよびナノ粒子ならびにその使用
WO2021243467A1 (en) * 2020-06-05 2021-12-09 London Pharmaceuticals And Research Corporation Cannabinoid-hyaluronic acid bioconjugates

Similar Documents

Publication Publication Date Title
JP6661744B2 (ja) HPTP−β阻害剤
JP2019504100A5 (cg-RX-API-DMAC7.html)
JP2016516068A5 (cg-RX-API-DMAC7.html)
BR112015006686A2 (pt) combinação de regorafenib e ácido acetilsalicílico para o tratamento de câncer.
JP2022516945A5 (cg-RX-API-DMAC7.html)
JP6855658B2 (ja) ポリエチレングリコールと局所麻酔薬とのコンジュゲートの非麻薬性鎮痛における使用
HRP20100559T1 (hr) Liječenje neovaskularnih poremećaja oka, poput makularne degeneracije, angioidnih strija, uveitisa i edema makule
TWI710555B (zh) 新穎水溶性前藥
RU2015129062A (ru) Соединения 3, 5-диамино-6-хлор-n-(n-(4-фенилбутил)карбамимидоил)пиразин-2-карбоксамида
JP2023544716A5 (cg-RX-API-DMAC7.html)
JP6034288B2 (ja) ルテニウム錯体を用いる併用療法
JP2021503449A5 (cg-RX-API-DMAC7.html)
CA3106568A1 (en) Therapeutic dendrimer
JP2002537251A (ja) 血管形成を伴う疾患の治療に対する併用
JP2007529426A5 (cg-RX-API-DMAC7.html)
US20260027088A1 (en) Inhibitors of Glutathione S-Transferases (GSTS) and NAD(P)H:Quinone Oxidoreductase 1 (NQO1), Pharmaceutical Compositions, and Uses in Managing Cancer
KR20230040957A (ko) 치료제를 국소 전달하기 위한 약물 전달 시스템 및 이의 용도
WO2021170811A1 (en) Method of treating eye disease using trpv4 antagonists
TW202133845A (zh) 用於預防或治療眼部疾病之眼用組合物
ES2978337T3 (es) Combinación de regonafenib y nivolumab para el tratamiento contra el cáncer
JP2019529472A5 (cg-RX-API-DMAC7.html)
JP2021138710A5 (cg-RX-API-DMAC7.html)
KR20120081585A (ko) 안질환을 치료하기 위한 이소티오졸
US20200054580A1 (en) Methods of treating a neurological or psychiatric disorder
US20160143914A1 (en) Nanoparticles for Encapsulation and Delivery of Bioactive Compounds and Compositions Thereof